ESMO2020: ipatasertib–abiraterone combination can be used to treat aggressive prostate cancers

Written by Sharon Salt, Future Science Group

ipatasertib

A major Phase III trial has demonstrated that a precision drug, termed ipatasertib, in combination with abiraterone can treat an aggressive group of prostate cancers that lack a functioning PTEN gene. These findings were presented at the European Society for Medical Oncology (ESMO) Virtual Congress (19–21 September 2020). These new results came from the IPATential150 study, which assessed the efficacy and safety of ipatasertib combined with abiraterone in men with advanced prostate cancer who had received no prior treatment. The trial included 1101 participants, of whom 521 lacked a fully functioning PTEN gene. Each person was given steroids in addition...

To view this content, please register now for access

It's completely free